By Frank Prenesti
Date: Monday 27 Jan 2020
(Sharecast News) - AstraZeneca said it had agreed to sell the global commercial rights to a range of hypertension treatments to Atnahs Pharma for up to $390m.
| Abbvie boss blasts US tax regime | 21-Oct-2014 | Telegraph |
| Drug company AbbVie takeover rival in £31bn bid | 18-Jul-2014 | Express & Star |
| AbbVie to announce firm bid for Shire | 18-Jul-2014 | Telegraph |
| AbbVie's raised proposal for Shire gets board ba... | 15-Jul-2014 | Guardian |
| Shire set to accept £31bn bid from US rival AbbVie | 15-Jul-2014 | Express & Star |
No recent information was found.
No recent information was found.
| Currency | US Dollars |
| Share Price | $ 229.25 |
| Change Today | $ 5.32 |
| % Change | 2.38 % |
| 52 Week High | $244.38 |
| 52 Week Low | $169.20 |
| Volume | 2,451,193 |
| Shares Issued | 1,765.26m |
| Market Cap | $404,685m |
| Beta | 0.51 |
| RiskGrade | 122 |
| Strong Buy | 7 |
| Buy | 13 |
| Neutral | 10 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 30 |

| Time | Volume / Share Price |
| 13:39 | 150 @ $229.25 |
| 13:39 | 100 @ $229.25 |
| 13:39 | 100 @ $229.22 |
| 13:39 | 100 @ $229.22 |
| 13:39 | 200 @ $229.21 |
You are here: research